慢性肾病

Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan;3(1):1-150.

• 全文

Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012 Apr 17;156(8):570-81.

• 摘要

Fox CS, Matsushita K, Woodward M, et al; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73.

• 全文
• 摘要

Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011 Apr 19;154(8):541-8.

• 全文
• 摘要

Locatelli F, Aljama P, Canaud B, et al; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant. 2010 Sep;25(9):2846-50.

• 全文
• 摘要

Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011 Jan;6(1):50-62.

• 全文
• 摘要

Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9(8):e1001293.

• 全文
• 摘要

1.  Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013 Jan;3(1):1-150.

• 全文

2.  Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007;11(2):R31.

• 全文
• 摘要

3.  Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003 Jan;41(1):1-12.

• 摘要

4.  Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ. 2006 Mar 11;332(7541):563-4.

• 摘要

5.  Hill NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney disease - a systematic review and meta-analysis. PLoS One. 2016 Jul 6;11(7):e0158765.

• 全文
• 摘要

6.  GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 28 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1211-59.

• 全文
• 摘要

7.  Rosenberg AZ, Kopp JB. Focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2017 Mar 7;12(3):502-17.

• 全文
• 摘要

8.  Jones CA, McQuillan GM, Kusek JW, et al. Serum creatinine levels in the US population: third National Health and Nutritional Examination Survey. Am J Kidney Dis. 1998 Dec;32(6):992-9.

• 摘要

9.  Freedman BI, Soucie JM, McClellan WM. Family history of end-stage renal disease among incident dialysis patients. J Am Soc Nephrol. 1997 Dec;8(12):1942-5.

• 全文
• 摘要

10.  Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012 Mar;81(5):442-8.

• 全文
• 摘要

11.  Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol. 2007 Oct;18(10):2644-8.

• 全文
• 摘要

12.  Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am. 2013 Jan;97(1):1-18.

• 摘要

13.  Persson F, Rossing P. Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl. 2018;8(1):2-7.

• 全文

14.  National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. United States Renal Data System, USRDS 2006 annual data report: Atlas of end-stage renal disease in the United States. 2006 [internet publication].

• 全文

15.  Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med. 1998 Nov 12;339(20):1448-56.

• 摘要

16.  Agarwal R. Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade. Am J Physiol Renal Physiol. 2003 Apr;284(4):F863-9.

• 全文
• 摘要

17.  Scivittaro V, Ganz MB, Weiss MF. AGEs induce oxidative stress and activate protein kinase C-beta(II) in neonatal mesangial cells. Am J Physiol Renal Physiol. 2000 Apr;278(4):F676-83.

• 全文
• 摘要

18.  National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis. 2012 Nov;60(5):850-86.

• 全文
• 摘要

19.  Calderon-Margalit R, Golan E, Twig G, et al. History of childhood kidney disease and risk of adult end-stage renal disease. N Engl J Med. 2018 Feb 1;378(5):428-38.

• 全文
• 摘要

20.  Shankar A, Klein R, Klein BE. The association among smoking, heavy drinking, and chronic kidney disease. Am J Epidemiol. 2006 Aug 1;164(3):263-71.

• 全文
• 摘要

21.  Ejerblad E, Fored CM, Lindblad P, et al. Obesity and risk for chronic renal failure. J Am Soc Nephrol. 2006 Jun;17(6):1695-702.

• 全文
• 摘要

22.  Tarver-Carr ME, Powe NR, Eberhardt MS, et al. Excess risk of chronic kidney disease among African-American versus white subjects in the United States: a population-based study of potential explanatory factors. J Am Soc Nephrol. 2002 Sep;13(9):2363-70.

• 全文
• 摘要

23.  Feldman HI, Klag MJ, Chiapella AP, et al. End-stage renal disease in US minority groups. Am J Kidney Dis. 1992 May;19(5):397-410.

• 摘要

24.  Helin HJ, Korpela MM, Mustonen JT, et al. Renal biopsy findings and clinicopathologic correlations in rheumatoid arthritis. Arthritis Rheum. 1995 Feb;38(2):242-7.

• 摘要

25.  Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005 Jan;16(1):180-8.

• 全文
• 摘要

26.  Silbiger SR, Neugarten J. The impact of gender on the progression of chronic renal disease. Am J Kidney Dis. 1995 Apr;25(4):515-33.

• 摘要

27.  Henrich WL, Clark RL, Kelly JP, et al. Non-contrast-enhanced computerized tomography and analgesic-related kidney disease: report of the National Analgesic Nephropathy Study. J Am Soc Nephrol. 2006 May;17(5):1472-80.

• 全文
• 摘要

28.  De Broe ME, Elseviers MM. Analgesic nephropathy. N Engl J Med. 1998 Feb 12;338(7):446-52.

• 摘要

29.  de Jong PE, Brenner BM. From secondary to primary prevention of progressive renal disease: the case for screening for albuminuria. Kidney Int. 2004 Dec;66(6):2109-18.

• 摘要

30.  Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Am J Kidney Dis. 2003 Oct;42(4):617-22.

• 摘要

31.  Montañés Bermúdez R, Gràcia García S, Pérez Surribas D, et al. Consensus document. Recommendations on assessing proteinuria during the diagnosis and follow-up of chronic kidney disease. Nefrologia. 2011;31(3):331-45.

• 全文
• 摘要

32.  Matsushita K, Mahmoudi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA. 2012 May 9;307(18):1941-51.

• 全文
• 摘要

33.  Agarwal R, Brunelli SM, Williams K, et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transpl. 2009 Mar;24(3):856-63.

• 摘要

34.  Collins AJ, Gilbertson DT, Snyder JJ, et al. Chronic kidney disease awareness, screening and prevention: rationale for the design of a public education program. Nephrology (Carlton). 2010 Jun;15 Suppl 2:37-42.

• 摘要

35.  Lv J, Ehteshami P, Sarnak MJ, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013 Aug 6;185(11):949-57.

• 全文
• 摘要

36.  James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014 Feb 5;311(5):507-20.

• 全文
• 摘要

37.  Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013 Nov;3(3):259-303.

• 全文

38.  Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92.

• 全文
• 摘要

39.  Fink HA, Ishani A, Taylor BC, et al. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012 Apr 17;156(8):570-81.

• 摘要

40.  Fox CS, Matsushita K, Woodward M, et al; Chronic Kidney Disease Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012 Nov 10;380(9854):1662-73.

• 全文
• 摘要

41.  Ku E, Glidden DV, Johansen KL, et al. Association between strict blood pressure control during chronic kidney disease and lower mortality after onset of end-stage renal disease. Kidney Int. 2015 May;87(5):1055-60.

• 摘要

42.  Casas J, Chua W, Loukogoergakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005 Dec 10;366(9502):2026-33.

• 摘要

43.  Hermida RC, Ayala DE, Mojón A, et al. Bedtime dosing of antihypertensive medications reduces cardiovascular risk in CKD. J Am Soc Nephrol. 2011 Dec;22(12):2313-21.

• 全文
• 摘要

44.  Sinha AD, Agarwal R. ACP Journal Club. Use of >= 1 antihypertensive drug at bedtime reduced CV events more than use of all drugs in the morning in CKD. Ann Intern Med. 2012 Jun 19;156(12):JC6-8.

• 摘要

45.  Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011 Apr 19;154(8):541-8.

• 全文
• 摘要

46.  Weir MR, Bakris GL, Weber MA, et al. Renal outcomes in hypertensive Black patients at high cardiovascular risk. Kidney Int. 2012 Mar;81(6):568-76.

• 摘要

47.  Tsai WC, Wu HY, Peng YS, et al. Association of intensive blood pressure control and kidney disease progression in nondiabetic patients with chronic kidney disease: a systematic review and meta-analysis. JAMA Intern Med. 2017 Jun 1;177(6):792-9.

• 摘要

48.  Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994 Mar 31;330(13):877-84.

• 全文
• 摘要

49.  Clase C. Renal failure (chronic). BMJ Clin Evid. 2011 May 25;2011:2004.

• 全文
• 摘要

50.  Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851-60.

• 全文
• 摘要

51.  Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9.

• 全文
• 摘要

52.  Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002 Nov 20;288(19):2421-31.

• 全文
• 摘要

53.  Balamuthusamy S, Srinivasam L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J. 2008 May;155(5):791-805.

• 摘要

54.  Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008 Apr 10;358(15):1547-59.

• 全文
• 摘要

55.  Parving HH, Brenner BM, McMurray JJ, et al; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012 Dec 6;367(23):2204-13.

• 全文
• 摘要

56.  Navaneethan SD, Hegbrant J, Strippoli GF. Role of statins in preventing adverse cardiovascular outcomes in patients with chronic kidney disease. Curr Opin Nephrol Hypertens. 2011 Mar;20(2):146-52.

• 摘要

57.  Jablonski KL, Chonchol M. Cardiovascular disease: should statin therapy be expanded in patients with CKD? Nat Rev Nephrol. 2012 Jul 3;8(8):440-1.

• 摘要

58.  Palmer SC, Craig JC, Navaneethan SD, et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21;157(4):263-75.

• 全文
• 摘要

59.  Upadhyay A, Earley A, Lamont JL, et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012 Aug 21;157(4):251-62.

• 摘要

60.  Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2014 May 31;(5):CD007784.

• 全文
• 摘要

61.  Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013 Sep 11;(9):CD004289.

• 全文
• 摘要

62.  Bakris GL, Weir MR, Secic M, et al. Differential effects of calcium antagonist subclasses on markers of nephropathy progression. Kidney Int. 2004 Jun;65(6):1991-2002.

• 摘要

63.  Segura J, García-Donaire JA, Ruilope LM. Calcium channel blockers and renal protection: insights from the latest clinical trials. J Am Soc Nephrol. 2005 Mar;16 Suppl 1:S64-6.

• 全文
• 摘要

64.  Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.

• 摘要

65.  Drüeke TB, Locatelli F, Clyne N, et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006 Nov 16;355(20):2071-84.

• 摘要

66.  Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 Nov 19;361(21):2019-32.

• 摘要

67.  KDIGO Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012 Aug;2(4):279-335.

• 全文

68.  Koulouridis I, Alfayez M, Trikalinos TA, et al. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis. Am J Kidney Dis. 2013 Jan;61(1):44-56.

• 摘要

69.  Wilhelm-Leen ER, Winkelmayer WC. Mortality risk of darbepoetin alfa versus epoetin alfa in patients with CKD: systematic review and meta-analysis. Am J Kidney Dis. 2015 Jul;66(1):69-74.

• 摘要

70.  Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017 Jul;7(1):1-59.

• 全文

71.  Coyne DW, Goldberg S, Faber M, et al. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6.

• 全文
• 摘要

72.  Jamal SA, Vandermeer B, Raggi P, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013 Oct 12;382(9900):1268-77.

• 摘要

73.  Association for Vascular Access, American Society of Diagnostic and Interventional Nephrology. Preservation of peripheral veins in patients with chronic kidney disease. Mar 2011 [internet publication].

• 全文

74.  Susantitaphong P, Sewaralthahab K, Balk EM, et al. Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review. Am J Nephrol. 2012;35(6):540-7.

• 摘要

75.  National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Jan 2007 [internet publication].

• 全文

76.  Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009 Feb;53(2):197-207.

• 摘要

77.  Garside R, Pitt M, Anderson R, et al. The effectiveness and cost-effectiveness of cinacalcet for secondary hyperparathyroidism in end-stage renal disease patients on dialysis: a systematic review and economic evaluation. Health Technol Assess. 2007 May;11(18):iii, xi-xiii, 1-167.

• 摘要

78.  O'Connor NR, Kumar P. Conservative management of end-stage renal disease without dialysis: a systematic review. J Palliat Med. 2012 Feb;15(2):228-35.

• 全文
• 摘要

79.  Blake PG, Bargman JM, Brimble KS, et al; Canadian Society of Nephrology Work Group on Adequacy of Peritoneal Dialysis. Clinical practice guidelines and recommendations on peritoneal dialysis adequacy 2011. Perit Dial Int. 2011 Mar-Apr;31(2):218-39.

• 摘要

80.  Berdud I, Arenas MD, Bernat A, et al; Grupo de Trabajo de Hemodiálisis Extrahospitalaria (Outpatient Haemodialysis Group). Appendix to dialysis centre guidelines: recommendations for the relationship between outpatient haemodialysis centres and reference hospitals. Opinions from the Outpatient Dialysis Group. Grupo de Trabajo de Hemodiálisis Extrahospitalaria. Nefrologia. 2011;31(6):664-9.

• 全文
• 摘要

81.  Clase CM, Smyth A. Chronic kidney disease: diet. BMJ Clin Evid. 2015 Jun 29;2015:2004.

• 全文
• 摘要

82.  Macdougall IC, Strauss WE, McLaughlin J, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014 Apr;9(4):705-12.

• 全文
• 摘要

83.  Liu Z, Su G, Guo X, et al. Dietary interventions for mineral and bone disorder in people with chronic kidney disease. Cochrane Database Syst Rev. 2015 Sep 16;(9):CD010350.

• 全文
• 摘要

84.  Vilayur E, Harris DC. Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol. 2009 Jul;5(7):375-83.

• 摘要

85.  Li R, Xing J, Mu X, et al. Sulodexide therapy for the treatment of diabetic nephropathy, a meta-analysis and literature review. Drug Des Devel Ther. 2015 Dec 3;9:6275-83.

• 全文
• 摘要

86.  Rhee SY, Kim YS. The role of advanced glycation end products in diabetic vascular complications. Diabetes Metab J. 2018 Jun;42(3):188-95.

• 全文
• 摘要

87.  Leporini C, Pisano A, Russo E, et al. Effect of pentoxifylline on renal outcomes in chronic kidney disease patients: a systematic review and meta-analysis. Pharmacol Res. 2016 May;107:315-32.

• 摘要

88.  Coca SG, Ismail-Beigi F, Haq N, et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med. 2012 May 28;172(10):761-9.

• 全文
• 摘要

89.  Jing Z, Wei-jie Y, Nan Z, et al. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One. 2012;7(8):e43655.

• 全文
• 摘要

90.  Albaramki J, Hodson EM, Craig JC, et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD007857.

• 全文
• 摘要

91.  Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006 Nov 16;355(20):2085-98.

• 摘要

92.  Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998 Aug 27;339(9):584-90.

• 全文
• 摘要

93.  Carrera F, Lok CE, de Francisco A, et al; PATRONUS Investigators. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. Nephrol Dial Transplant. 2010 Dec;25(12):4009-17.

• 全文
• 摘要

94.  Locatelli F, Aljama P, Canaud B, et al; Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) study. Nephrol Dial Transplant. 2010 Sep;25(9):2846-50.

• 全文
• 摘要

95.  Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol. 2011 Jan;6(1):50-62.

• 全文
• 摘要

96.  Alvarez J, Wasse H, Tangpricha V. Vitamin D supplementation in pre-dialysis chronic kidney disease: a systematic review. Dermatoendocrinol. 2012 Apr 1;4(2):118-27.

• 全文
• 摘要

97.  National Kidney Foundation. KDOQI clinical practice guidelines: nutrition in chronic renal failure. Am J Kidney Dis. 2000 Jun;35(6 Suppl 2):S1-140.

• 全文
• 摘要

98.  Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998 Nov;32(5):853-906.

• 摘要

99.  KDOQI Workgroup. KDOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005 Apr;45(4 Suppl 3):S1-153.

• 全文
• 摘要

100.  Molitoris BA, Froment DH, Mackenzie TA. Citrate: a major factor in the toxicity of orally administered aluminum compounds. Kidney Int. 1989 Dec;36(6):949-53.

• 摘要

101.  Warnock DG. Uremic acidosis. Kidney Int. 1988 Aug;34(2):278-87.

• 摘要

102.  Lv J, Neal B, Ehteshami P, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: a systematic review and meta-analysis. PLoS Med. 2012;9(8):e1001293.

• 全文
• 摘要